Ralph Oiknine, MD
Endocrinology, Diabetes & Metabolism · Chesterfield, MONPI 1255365581
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,139 of the $144,324 with a category attached, or 76.3%. It is spread thinly across 49 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2019 at $41,280 and has fallen 74.2% since, to $10,666 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 552 payments — averaging $261.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$33K
- AstraZeneca$29K
- AbbVie$21K
- Johnson & Johnson$18K
- Boehringer Ingelheim$15K
- Lilly USA, LLC$8K
- plus $19K from 43 others
Across 44 payments — averaging $6170.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Senseonics, Incorporated$262K
- Eli Lilly$9K
What the payments were for
- Consulting fees$15,46311%
- Speaking & faculty fees$110,13976%
- Travel & lodging$7,2645%
- Food & beverage$11,2588%
- Education$1420%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$22,833
- JARDIANCE$21,975
- RYBELSUS$21,645
- Synthroid$21,049
- INVOKANA$17,756
- Ozempic$10,805
- BYDUREON$5,558
- Omnipod$4,908
- DISEASE STATE$2,530
- V-GO$2,203
- Eversense$1,318
- FreeStyle Libre Pro$1,138
- InPen$582
- iLet Bionic Pancreas$571
- MINIMED 780G$571
- EVERSENSE E3 SENSOR KIT - RETAIL$450
- MINIMED 770G$199
- TWIIST$149
- Wegovy$128
- DEXCOM G6 TRANSMITTER$116
How this compares
$144,324 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,073 | $1,870,011 |
| MounjaroTirzepatide | 509 | $757,488 |
| TrulicityDulaglutide | 445 | $729,877 |
| FarxigaDapagliflozin Propanediol | 523 | $620,767 |
| JardianceEmpagliflozin | 369 | $480,872 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 269 | $364,791 |
| Tresiba Flextouch U-100Insulin Degludec | 271 | $171,614 |
| Humalog Kwikpen U-200Insulin Lispro | 32 | $134,635 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 92 | $105,932 |
| JanuviaSitagliptin Phosphate | 89 | $105,498 |
| InvokanaCanagliflozin | 63 | $100,905 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $81,875 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $76,955 |
| HumalogInsulin Lispro | 205 | $74,035 |
| NovologInsulin Aspart | 162 | $68,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Tresiba | $33,248 | $1,954,1021,248 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $8,289 | $1,561,3991,159 claims |
| AstraZenecaFarxiga | $29,461 | $620,767523 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $14,808 | $570,839428 claims |
| MerckJanuvia, Janumet Xr, Janumet | $101 | $177,353146 claims |
| Johnson & JohnsonInvokana | $18,192 | $100,90563 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $2,830 | $41,93987 claims |
| AbbVieSynthroid | $21,476 | $37,351372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Chesterfield
- Karen Chang-ChenChesterfield$640K
- Soumya NadellaChesterfield$8K
- Norman FishmanChesterfield$4K
- Ralph DudaSpringfield$644K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.